MX2021003551A - Metodos de tratamiento de infecciones utilizando bacterias. - Google Patents

Metodos de tratamiento de infecciones utilizando bacterias.

Info

Publication number
MX2021003551A
MX2021003551A MX2021003551A MX2021003551A MX2021003551A MX 2021003551 A MX2021003551 A MX 2021003551A MX 2021003551 A MX2021003551 A MX 2021003551A MX 2021003551 A MX2021003551 A MX 2021003551A MX 2021003551 A MX2021003551 A MX 2021003551A
Authority
MX
Mexico
Prior art keywords
methods
infections
bacteria
treatment
compositions
Prior art date
Application number
MX2021003551A
Other languages
English (en)
Inventor
Michael J Newman
Original Assignee
Decoy Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decoy Biosystems Inc filed Critical Decoy Biosystems Inc
Publication of MX2021003551A publication Critical patent/MX2021003551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se refiere en general a composiciones, formas de dosificación, y métodos para prevenir y tratar infecciones. Las infecciones incluyen células bacterianas Gram-negativas intactas y sustancialmente no viables que se han tratado para reducir actividad de endotoxina asociada con lipopolisacárido (LPS) que tienen sorprendentemente actividad incrementada para activar la producción de células inmunitarias de las citocinas.
MX2021003551A 2018-09-27 2019-09-26 Metodos de tratamiento de infecciones utilizando bacterias. MX2021003551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737762P 2018-09-27 2018-09-27
PCT/US2019/053289 WO2020069211A1 (en) 2018-09-27 2019-09-26 Methods of treatment of infections using bacteria

Publications (1)

Publication Number Publication Date
MX2021003551A true MX2021003551A (es) 2021-08-16

Family

ID=69947978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003551A MX2021003551A (es) 2018-09-27 2019-09-26 Metodos de tratamiento de infecciones utilizando bacterias.

Country Status (14)

Country Link
US (2) US11147844B2 (es)
EP (1) EP3856213B1 (es)
JP (1) JP2022502439A (es)
KR (1) KR20210068462A (es)
CN (1) CN112770764A (es)
AU (1) AU2019347502A1 (es)
BR (1) BR112021005762A2 (es)
CA (1) CA3114110A1 (es)
DK (1) DK3856213T3 (es)
EA (1) EA202190546A1 (es)
FI (1) FI3856213T3 (es)
IL (1) IL281775A (es)
MX (1) MX2021003551A (es)
WO (1) WO2020069211A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045498B (zh) * 2021-03-24 2023-01-24 江苏食品药品职业技术学院 一种1,5-二芳基吡唑衍生物、合成方法及用途
CN114717178A (zh) * 2022-03-03 2022-07-08 中国医学科学院医学生物学研究所 一种树鼩睾丸间质细胞的分离培养方法及其应用
WO2024107543A1 (en) * 2022-11-17 2024-05-23 Indaptus Therapeutics, Inc. Treatment of cancers and infectious diseases with killed intact bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
ITRM20030394A1 (it) * 2003-08-12 2005-02-13 Maria Gabriella Santoro Uso dell'indometacina e derivati come farmaci antivirali e relative composizioni farmaceutiche.
TWI664976B (zh) 2013-01-02 2019-07-11 美商迪科生物系統公司 使用細菌治療癌症之組成物和方法
HUE052575T2 (hu) * 2014-12-18 2021-05-28 Helperby Therapeutics Ltd Új kombináció és alkalmazás
US20200056145A1 (en) * 2017-04-17 2020-02-20 The Regents Of The University Of California Engineered commensal bacteria and methods of use
CN107184613A (zh) * 2017-05-23 2017-09-22 山东大学 一种促进乙型肝炎病毒清除的益生菌组合物及其应用

Also Published As

Publication number Publication date
EP3856213A4 (en) 2022-07-06
CN112770764A (zh) 2021-05-07
BR112021005762A2 (pt) 2021-06-29
US20220031768A1 (en) 2022-02-03
US11147844B2 (en) 2021-10-19
KR20210068462A (ko) 2021-06-09
WO2020069211A1 (en) 2020-04-02
EP3856213B1 (en) 2024-03-06
FI3856213T3 (fi) 2024-05-30
JP2022502439A (ja) 2022-01-11
EP3856213A1 (en) 2021-08-04
AU2019347502A1 (en) 2021-04-22
IL281775A (en) 2021-05-31
DK3856213T3 (da) 2024-05-27
US20200101119A1 (en) 2020-04-02
CA3114110A1 (en) 2020-04-02
EA202190546A1 (ru) 2021-09-10

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2021003551A (es) Metodos de tratamiento de infecciones utilizando bacterias.
PH12019500360A1 (en) Antibiotic compounds
MX2017010710A (es) Composición terapeútica y profiláctica producida por microbiota.
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
MX2016009898A (es) Tratamientos para acne resistente.
WO2019067380A3 (en) Treatment of mosaic viruses and bacterial infections of plants
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
WO2018231992A3 (en) METHODS OF USING LACTOBACILLUS PLANTARUM STRAINS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIAL INFECTION
WO2017160944A3 (en) Compositions and methods for treating and preventing graft versus host disease
ZA202002093B (en) Antibacterial compounds
PH12019502056A1 (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
MX2017009094A (es) Derivado de polimixina y usos del mismo.
ZA202006612B (en) Antibacterial compounds
WO2018170238A3 (en) Methods and compositions for inducing immune responses against clostridium difficile
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
WO2016191695A3 (en) Treatments for obligately intracellular infections
IL299751A (en) Preparations and methods for disinfection, treatment and prevention of bacterial infections
MX2020001501A (es) Streptococcus australis como bioterapeuticos.